-
Mashup Score: 9Medicare Part B Spending on Macular Degeneration Treatments - 7 month(s) ago
This cross-sectional study evaluates whether research and nonresearch payments from drug manufacturers play a role in opthalmologists’ selection of therapies for age-related macular degeneration.
Source: jamanetwork.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 14ESMO Congress 2023: Programme - 7 month(s) ago
The ESMO 2023 Programme is now online!
Source: www.esmo.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @myESMO: #ESMO23: All regular abstracts (proffered paper & mini oral sessions) and posters can be found online👉https://t.co/ZXVaQjrhoV T…
-
#ESMO23: All regular abstracts (proffered paper & mini oral sessions) and posters can be found online👉https://t.co/ZXVaQjrhoV The countdown is on ⏰ Just four days before Congress begins. If you haven’t registered yet there's still time to do so 👉https://t.co/pL873WfUxO… https://t.co/Le8uBa079Y https://t.co/4WTM6IiVfb
-
-
Mashup Score: 0Lung cancer rates for younger, middle-aged women higher than men's - 7 month(s) ago
GMA is your source for useful news and inspiration on how to live your best life. Your community and guide to relationship advice, the latest in celebrity news, culture, style, travel, home, finances, shopping deals, career and more.
Source: www.goodmorningamerica.comCategories: Latest Headlines, Oncologists1Tweet-
#Lungcancer rates are ⬆️ for women, including 🚺 <50: new study from @AmericanCancer. Thanks to @GMA for bringing much needed awareness to #lungcancer. @IASLC @LUNGevity @OncoAlert @lcfamerica @lcrf_org https://t.co/KtggpT8S7J
-
-
Mashup Score: 4How to Bring Basic Science Discoveries to the Clinic | EACR-AACR-IACR Basic and Translational Research Conference - 7 month(s) ago
The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR). Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic
Source: www.eai2024.orgCategories: Latest Headlines, Oncologists1Tweet-
Join us in Ireland! Abstract submission deadline tomorrow 10-16-23. Great group of faculty in a beautiful location! Full program here: https://t.co/zHRjWNOC9b @AACR @EACRnews @DrJNaidoo https://t.co/RTrJFfqrsV
-
-
Mashup Score: 2Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements - 7 month(s) ago
Zenocutuzumab, a HER2xHER3 bispecific antibody, reduces cell growth in NRG1-rearranged cancer cell lines and xenografts and induces durable clinical responses in patients with NRG1 fusion–positive tumors.
Source: aacrjournals.orgCategories: Latest Headlines, Oncologists1Tweet-
➡️ Zenocutuzumab (aka Zeno) This is a great #PrecisionMedicine story! ➡️ HER2xHER3 bispecific Ab ➡️ “Dock and Block” MOA ➡️ Tested in pan cancer with rare NRG1 fusions @CD_AACR @MSKCancerCenter https://t.co/aagxAhuZnD
-
-
Mashup Score: 9100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 8 - Oncodaily | Oncology News, Insights, Stories - 7 month(s) ago
Once again, it’s Saturday, and we continue OncoDaily’s series, ‘100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2023.’ As
Source: oncodaily.comCategories: Latest Headlines, Oncologists1Tweet-
RT @oncodaily: 100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 8 https://t.co/aXKwkoAMf1 🇺🇸…
-
-
Mashup Score: 0Tradition of cellular therapy innovation continues to improve cancer care at Ohio State - 7 month(s) ago
Decades of cellular therapy research led to a breakthrough in blood cancer care at Ohio State while building a base for a future of continued innovation in patient care.
Source: cancer.osu.eduCategories: Latest Headlines, Oncologists1Tweet-
The @OSUCCC_James has long been at the forefront of CAR T-cell therapy, and continues to innovate thanks to the work of Dr. Samantha Jaglowski and her colleagues. https://t.co/dqVf9p28lQ
-
-
Mashup Score: 3Probiotic-guided CAR-T cells for solid tumor targeting - 7 month(s) ago
Engineered probiotics produce synthetic targets to facilitate immunotherapy of solid tumors by CAR T cells.
Source: www.science.orgCategories: Latest Headlines, Oncologists1Tweet-
RT @DrMvandenBrink: Probiotic-guided CAR-T cells for solid tumor targeting | Science https://t.co/WvExykuEL3
-
-
Mashup Score: 6Metastatic Breast Cancer Support and Education - Dana-Farber Cancer Institute | Boston, MA - 7 month(s) ago
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program is to provide resources and information to help guide patients through many situations and decisions. Throughout their journey, metastatic breast cancer patients in the EMBRACE program receive education and support from expert clinicians, other professionals, and one another.
Source: www.dana-farber.orgCategories: Latest Headlines, Oncologists1Tweet-
Excited to kick off our annual virtual #EMBRACE #MBC forum for patients and loved ones on October 28! Registration is free. https://t.co/9EUAneN9GF https://t.co/MwhlQkjr9Y
-
-
Mashup Score: 0Cell/Gene Therapy Is Ripe For Real-World Data Given Length Of Follow-Up Required, Abernethy Says - 7 month(s) ago
The former principal deputy commissioner outlined what she sees as the future data requirements for real world evidence and why cell and gene therapy will lead the way.
Source: pink.citeline.comCategories: Latest Headlines, Oncologists1Tweet-
Cell and gene therapies will require new evidence generation approaches to meet regulatory requirements for long term follow-up. This @PharmaPinkSheet article by @Kate_Rawson covers my remarks at @CancerResrch’s meeting on how we can build what’s needed. https://t.co/veH1hA5qdt
-
"we found that payments from manufacturers of macular degeneration drugs to ophthalmologists were the largest factor in reduced bevacizumab use, exceeding the variations associated with patient or ophthalmologist characteristics." https://t.co/fiIhIvOK1S